Investigational drug · Phase 2
ENX-102
Also called: ENX-102 -dose, ENX-102 mid-dose
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for General Anxiety Disorder, Social Anxiety Disorder (SAD), Generalized Anxiety Disorder.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
0 still active
All registered trials
3
Any phase or sponsor naming "ENX-102"
First trial start
2023
Jul 3, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ENX-102", any sponsor or status.
Conditions studied
As listed on its trial records.
- General Anxiety Disorder
- Social Anxiety Disorder (SAD)
- Generalized Anxiety Disorder
Approved drugs for the same conditions: Anxiety disorders · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "ENX-102" as an intervention, largest first.
- ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety DisorderPivotal-lookingCompleted
Engrail Therapeutics INCIndustry
NCT05749055 · 252 participants · Start Jul 3, 2023 · Primary completion Sep 18, 2025
Drug: ENX-102; Placebo · For: Generalized Anxiety Disorder
Sites: Phoenix, Arizona; Garden Grove, California; Imperial, California · 32 sites in all
- A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety DisorderCompleted
Engrail Therapeutics INCIndustry
NCT07193563 · 47 participants · Start Sep 5, 2025 · Primary completion Mar 19, 2026
Drug: ENX-102 · For: Social Anxiety Disorder (SAD)
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 20 sites in all
Engrail Therapeutics INCIndustry
NCT06653296 · 38 participants · Start Dec 9, 2024 · Primary completion Jun 23, 2025
Drug: ENX-102; Placebo · For: General Anxiety Disorder
Sites: Liverpool, United Kingdom; Blackpool, United Kingdom; Manchester, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Biomarker-Based Pharmacological Characterization of ENX-102, a Novel α2/3/5 Subtype-Selective GABAA Receptor Positive Allo-Steric Modulator: Translational Insights from Rodent and Human Studies.
Nettesheim P, Vadodaria KC, Vanover KE, et al. · Cells 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.